Monday, September 18, 2023 9:40:38 PM
That is awesome information to have on this board DC. Thank you very much for that.
As i was thinking about the GBM criteria you outlined, it's a reasonable criteria standard, imo
The GBM patients biggest challenge is survivability so the PFS criteria makes sense, imo
What's your take on today's news regarding David Epstein's move out of the CEO position and replaced by Mark Valleca?
https://www.bizjournals.com/boston/news/2023/09/18/black-diamond-therapeutics-david-epstein-ceo.html?utm_source=sy&utm_medium=nsyp&utm_campaign=yh
As i was thinking about the GBM criteria you outlined, it's a reasonable criteria standard, imo
The GBM patients biggest challenge is survivability so the PFS criteria makes sense, imo
What's your take on today's news regarding David Epstein's move out of the CEO position and replaced by Mark Valleca?
https://www.bizjournals.com/boston/news/2023/09/18/black-diamond-therapeutics-david-epstein-ceo.html?utm_source=sy&utm_medium=nsyp&utm_campaign=yh
Recent BDTX News
- Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting • GlobeNewswire Inc. • 04/21/2026 02:40:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/16/2026 08:12:07 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/16/2026 08:03:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 08:02:04 PM
- Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/16/2026 08:01:00 PM
- Black Diamond Therapeutics to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 03/02/2026 09:01:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/17/2026 09:09:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2026 09:05:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2026 09:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2026 09:05:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2025 09:33:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/03/2025 01:20:44 PM
- Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM • GlobeNewswire Inc. • 12/03/2025 12:01:00 PM
- Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update • GlobeNewswire Inc. • 12/02/2025 09:01:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/13/2025 10:20:14 PM
- Black Diamond Therapeutics to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 11/06/2025 09:01:00 PM
- Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/06/2025 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2025 12:12:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2025 12:01:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/22/2025 09:45:37 PM
- Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/07/2025 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2025 11:04:19 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2025 11:01:46 AM
- Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/29/2025 12:00:00 PM
